Replies to post #817 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Data from another group with one-year follow-up demonstrating the safety and efficacy of an auto anti-BCMA/CD19 CAR-T cell therapy in patients with refractory myasthenia gravis. They identified FCRL5 as target in patients who relapse https://www.science.org/doi/10.1126/sciadv.aeb6424

Preclinical data on an anti-FCRL5 CAR-T https://www.nature.com/articles/s41392-023-01702-2